Increased influence of genetic variation on PON1 activity in neonates. by Chen, Jia et al.
Chlorpyrifos, an insecticide implicated as a
developmental neurotoxin in animals (Shih
et al. 1998), has been used routinely in the
homes of urban populations in the United
States. The biochemical contributions of
metabolizing enzymes to the neurotoxic
potential of chlorpyrifos and other
organophosphates remain subjects of active
investigation (Sams et al. 2000; Costa et al.
1999; Furlong et al. 2000). Specifically,
after activation of chlorpyrifos to the reac-
tive oxon, the oxon may be detoxified by
PON1 (paraoxonase-1) before it has the
chance to inactivate acetylcholinesterase in
the peripheral nervous system (PNS) and
central nervous system (CNS). PON1,
which is associated with high-density lipid
lipoprotein (HDL), also functions to cleave
oxidized lipids in low-density lipid lipo-
protein (LDL) as well as in HDL (Aviram
et al. 1998, 2000). PON1 also has an
arylesterase activity (Gan et al. 1991).
HDL levels and PON1 activities are some-
what elevated during pregnancy (Roy et al.
1994). As part of the continuing effort of
the Mount Sinai Children’s Environmental
Health Center to prospectively assess the
neurodevelopmental risks associated with
chlorpyrifos exposure in an inner-city pop-
ulation in New York City, we investigated
the genetic determinants of chlorpyrifos
metabolism in a population of ethnically
diverse mothers and their neonates. In this
study, we examined the hypothesis that
genetic factors may be more crucial in
determining risk in neonates than in adults
of various ethnicities.
The  PON1 gene has been fully
characterized (Clendenning et al. 1996)
and has been found to be a member of a
multigene family of three linked genes,
PON1 (MIM 168820), PON3 (MIM
602720), and PON2 (MIM 602447)
(OMIM 2002), in that order (Primo-
Parmo et al. 1996; Entrez Chromosome
Map 2002). Human PON1 had long been
recognized to be polymorphic based both
on large differences in serum PON1 activ-
ity (Geldmacher-von Mallinckrodt et al.
1983) and on the phosphodiesterase/
arylesterase activity ratio for different sub-
strates, including organophosphate oxons
derived from pesticides and direct-acting
cholinesterase inhibitors such as the nerve
gas sarin (Davies et al. 1996). The puriﬁed
isozymes retained these differences in
organophosphate hydrolysis activity nor-
malized to arylesterase activity (Smolen et
al. 1991). PON1 contains two common
polymorphisms in the coding region,
Q192R (Adkins et al. 1993; Humbert et al.
1993) and L55M (Garin et al. 1997), and
three common polymorphisms in the pro-
moter at –909, –162 and –108 (Leviev and
James 2000; Brophy et al. 2001a, 2001b).
Promoter variants in PON1 affect the level
of expression by more than 2-fold (Boright
et al. 1998; Brophy et al. 2001a, 2001b).
Q192R affects the relative rate of hydrolysis
of certain organophosphate substrates com-
pared with phenyl acetate by as much as an
order of magnitude but has only a small
effect on chlorpyrifos oxon/phenylacetate
rate of hydrolysis (Davies et al. 1996). The
L55M polymorphism has been found to
affect lipid peroxidation (Malin et al. 2001)
and PON1 protein stability (Leviev et al.
2001), although the recent work on pro-
moter mutations has suggested that the
apparent effect of the L55M polymorphism
on enzyme concentration also may be due to
linkage disequilibrium (LD) with one of the
promoter variants (Brophy et al. 2001b).
Toxicity of chlorpyrifos is inversely
related to serum PON1 activity. Intravenous
injection of PON1 before challenge by
chlorpyrifos is protective in the rat (Costa et
al. 1990). PON1 knockout mice were more
susceptible to chlorpyrifos toxicity (Shih et
al. 1998), and the toxicity was alleviated by
intraperitoneal injection of puriﬁed PON1,
with the 192RR (homozygous) enzyme pro-
viding better protection than 192QQ (Li et
al. 2000). Using the rat model, Attenberry
et al. (1997) have demonstrated that the
age-related decrease in susceptibility to
chlorpyrifos CNS toxicity is not due to
either the rate of activation to the oxon or to
the reactivity of the oxon in the CNS but is
entirely due to age-related differences in the
detoxification of the oxon. Developing
human fetuses have much lower protective
PON1 activities than do adults, with the
level in cord blood being severalfold lower
(Mueller et al. 1983). Furthermore, both
chlorpyrifos and chlorpyrifos oxon can cross
the placenta. Subcutaneous delivery of a
high dose of chlorpyrifos to pregnant rats
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PON1 (paraoxonase-1) detoxiﬁes organophosphates by cleavage of active oxons before they have a
chance to inhibit cholinesterases. The corresponding gene PON1 has common polymorphisms in
both the promoter (–909, –162, –108) and the coding region (L55M, Q192R). The ﬁve PON1
genotypes were determined for maternal blood (n = 402) and cord blood (n = 229) as part of a
study of the effects of organophosphate pesticide exposure on infant growth and neurodevelop-
ment. PON1 enzymatic activities were determined for a majority of subjects. The population
contained Caucasians, Caribbean Hispanics, and African Americans. PON1 activity was strongly
dependent upon the promoter alleles in both maternal and cord blood. For example, PON1 activ-
ities for position –108CC, CT, and TT mothers were 146, 128, and 109 arylesterase U/mL
(analysis of variance, p < 0.0001), whereas the same PON1 activities for the respective cord
bloods were 49.0, 32.4, and 23.2 U/mL (p < 0.0001). Compared with adults, neonates had lower
PON1 activity, implying reduced capacity to detoxify organophosphates. In addition there was a
larger difference in activity between genotype groups in neonates than in adults. Because the ﬁve
polymorphisms in PON1 occur in a short stretch of DNA, they were tested for linkage disequilib-
rium (LD). Significant LD was found among all three promoter polymorphisms as well as
between promoter polymorphisms and L55M, with the strongest LD for Caucasians and the
weakest for African Americans. The Caribbean Hispanics fall between these two groups.
Surprisingly, signiﬁcant LD also was observed between the promoter polymorphisms and C311S
in PON2. LD between the promoter polymorphisms and Q192R was not signiﬁcant. Key words:
children, chlorpyrifos, linkage disequilibrium, neonate, pesticide, polymorphism, PON1, preg-
nancy. Environ Health Perspect 111:1403–1410 (2003). doi:10.1289/ehp.6105 available via
http://dx.doi.org/ [Online 7 May 2003]
Toxicogenomics Articleled to significant (30–49%) inhibition of
fetal acetylcholinesterase activity (Chanda
and Pope 1996). Thus, both fetuses and
very young children may be more suscepti-
ble to pesticide exposure compared with
adults. Lower PON1 activities may reflect
increased risk after acute or chronic expo-
sure to chlorpyrifos in utero and in the
neonatal period.
Using maternal and cord blood, we have
carried out a systematic study of the origin
and extent of variation in PON1 activities in
our population of three racial/ethnic groups
comprising the majority of many inner-city
populations: Caucasians, African Americans,
and Caribbean Hispanics. Specifically, we
address genotype–phenotype relationships
for all ﬁve polymorphisms and note differ-
ences among these three racial/ethnic
groups, highlighting the differences between
mothers and neonates. We also address LD
among the ﬁve polymorphisms, noting dif-
ferences among of three racial/ethnic groups
that will affect inference of haplotypes.
Subjects and Methods
Study Population
This study is part of an ongoing prospective
study of the effect of pesticide exposure on
infant growth and neurodevelopment con-
ducted at the Mount Sinai School of
Medicine. The study protocol was approved
by the institutional review board. A total of
479 pregnant women scheduled to deliver
at Mount Sinai Hospital and their neonates
were enrolled in the study. Seventy-seven of
these women have been excluded because of
medical complications, terminations of
pregnancy, very premature births, failure to
collect specimens from the women before
they gave birth, delivery of an infant with
birth defects, change of residence, or refusal
to continue to participate. A total of 402
maternal blood samples were obtained from
individuals self-identified as being
Caucasian (n = 82), African American
(n = 117), or Hispanic (n = 203, predomi-
nantly of Caribbean origin). Maternal
blood was collected in heparin-treated
Vacutainer tubes (Becton, Dickinson and
Co., Franklin Lakes, NJ) at about 26–30
weeks of gestation. At birth, a sample of
umbilical cord blood was obtained for
229 infants (Caucasian n = 56, African
American n = 66, Caribbean Hispanic n =
107). Cord blood was collected with the
same anticoagulant. Although EDTA is a
better anticoagulant for long-term DNA
storage and polymerase chain reaction
(PCR), it cannot be used because it inhibits
and destabilizes PON1. Plasma was sepa-
rated immediately (within 24 hr) by two
cycles of centrifugation. Three aliquots of
maternal plasma and three aliquots of cord
blood plasma were frozen at –70°C, one for
determination of PON1. The buffy coat
was separated from the red blood cells, and
DNA was extracted and purified using a
QIAamp blood kit (Qiagen, Valencia, CA)
as described by the manufacturer.
Genotyping
All PCR reactions were assembled using
standard precautions in an ultraviolet-
irradiated hood in a room dedicated to this
purpose to prevent carryover contamina-
tion. The PON1 –909G→C, L55M, and
Q192R and the PON2 C311S genotypes
were determined by the clamp-dependent
allele-specific PCR (CD-ASPCR) method
of Germer and Higuchi (1999). Real-time
PCR methods was selected because it is a
single-tube assay and offers high through-
put. The primer sequences for genotyping
were as follows:
–909G→C: G (sense), 5´-TGCCTCT-
GTACAACCATGTC–3´; C (sense),
5´-CGGCGGGGGCGGTGCCTC-
TGTACAACCATGTG-3´; reverse, 5´-
CATGGAGCAAATCATTCACAG-3´. 
L55M: M, 5´-GGCAGAAACTGGCTC-
TGAAGACA-3´; L, 5´-CGGCGGGG-
GCGCGGCAGAAACTGGCTCTGA
AGACT; reverse, 5´-CACTCACAGA-
GCTAATGAAAGCC-3´. 
Q192R: Q, 5´-TATTTTCTTGACCCC-
TACTTACA-3´; R, 5´-CGGCGGGG-
GCGGGGCTTTCTTGACCCCTAC
TTACG-3´; reverse, 5´-CTTCACTT-
GGACTATAGTAGACAA-3´. 
PON2 C311S: S, 5´-CGGCGGCGGC-
CGCATCCA-3´; C, 5´-TCCGCAT-
CCA-GAACATTCTATG-3´; reverse,
5´-ACACTGAGGCTACAGAACTT-
CC-3´. 
The –108C→T and –162A→G
genotypes were determined by restriction
fragment length polymorphism analysis
of PCR products (Brophy et al. 2001a). For
–108C→T, heminested PCR was per-
formed first with the primers 5´-TG-
GGCGCAGACACCGACGGG-3´ and
5´-GCCCAGCTAGCTGCCGACCC-3´
and after 1,000-fold dilution with 5´-
TGGGCGCAGACACCGACGGG-3´ and
5´-CTAGCTGCCGACCCGGCCCA-
GAGGGG-3´. The products were digested
with BstXI. For –162A→G, the primers
were 5´-CCAGGTGCACAGAAGGCG-3´
and 5´-GCTCCTGCGGTGGGGGC-
TGA-3´, and the restriction endonuclease
was BstUI. For each coded sample, geno-
types were entered into the laboratory data-
base and veriﬁed by a second investigator.
PON1 Assay
The hydrolysis of phenylacetate to acetic
acid and phenol, measured by absorbance
maximum A270, was used to determine
human plasma PON1 activity using the
standard definition of units (Furlong et al.
1989). The molar extinction coefficient of
phenol is 1,310. On the order of 5% of
the PON1 activity in plasma may be due
to serum cholinesterase and serum albu-
min (Gan et al. 1991). This contribution
was minimized by performing the assays
at high pH. A cholinesterase inhibitor, in
this case eserine sulfate, is also necessary
for specificity. The assay was first per-
formed as described in a Hewlett-Packard
diode array spectrophotometer (Agilent,
Palo Alto, CA) equipped with a cell
holder equipped with a thermostat. The
assay was then adapted to 96-well format
for high throughput and replication. A
buffer solution (1.2×) was prepared as 12
mM Tris–HCl (pH 8.0), 1.2 mM CaCl2,
6µ M EDTA, and 4.8 µM eserine sulfate.
Individual plasma samples were diluted
333-fold by addition of 3 µL plasma per
milliliter phosphate-buffered saline.
Phenylacetate was dissolved in water at
36 mM (10×) immediately before use and
mixed with nine parts buffer. Two hun-
dred microliters of this mixture were
added to each well. Twenty-microliter
aliquots of diluted plasma were placed in
individual wells. The plates were incu-
bated at 37°C in a Bio-Tek PowerwaveX
microplate reader (Bio-Tek, Winooska,
VT). The increase in A270 was followed
over time. The slope of the kinetic curve
determined by the instrument software
was used to calculate the rate of hydrolysis
of phenylacetate. Blanks included both
samples lacking plasma and samples with
plasma but lacking substrate. The mea-
surements of individual samples were
reproducible within 10%, mostly limited
by the serum dilution step.
Statistical Analysis
The genetic influence of PON1 poly-
morphisms on PON1 activity was analyzed
by analysis of variance. Because of limited
serum availability for enzymatic activity
determinations, a total of 390 maternal and
189 neonate data sets were analyzed. Log
transformation of the enzyme activity was
performed to improve normality. Linear
regression was used to assess age-adjusted
trends in genotypic effects on PON1 phe-
notypes. These relationships were exam-
ined separately in mothers and neonates as
well as by race/ethnicity. LD was calculated
as D´ based on Lewontin, which ranges
from 0 (no LD) to 1 or –1 (complete LD)
(Lewontin 1988). The EH (estimating
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(Terwilliger and Ott 1994) was used to
determine chi-square statistics and p-values
for tests of allelic association between poly-
morphic markers. To assess independent
and group effects of polymorphisms on
PON1 activity, linear and multivariable
regression models were used to determine
the independent and group contributions
of the coding and promoter polymor-
phisms to phenotypic expression based on
Brophy et al. (2001b). All p-values are two-
sided. Statistical tests were performed using
SAS (SAS Institute 2001).
Results
PON Allele Frequencies
Single nucleotide polymorphism (SNP)
frequencies were obtained for the five
common PON1 polymorphisms and for
one common PON2 polymorphism
(Table 1). The promoter alleles are
named in the sense direction. Although
the allele frequencies varied substantially
among race/ethnicity groups, each of the
six polymorphisms has a minor allele fre-
quency of at least 11% in all of the ethnic
groups.
PON1 Genotypes and 
PON1 Activity
The maternal geometric mean PON1
activity was independent of race/ethnicity,
with mean values of 123, 131, and 130
U/mL for African Americans, Caucasians,
and Caribbean Hispanics, respectively
(p =0 .08). Effects of maternal genotypes
and race/ethnicity on maternal PON1
activity are summarized in Table 2.
Overall, a statistically signiﬁcant (p ≤ 0.02)
difference in PON1 activity was found
among genotypes of each of the three pro-
moter polymorphisms as well as L55M.
The Q192R polymorphism did not influ-
ence PON1 activity with phenylacetate.
When examined by race/ethnicity indepen-
dently, L55M was not a signiﬁcant predic-
tor (p = 0.14) in Caucasian mothers,
whereas the promoter polymorphisms were
not significant predictors in African-
American mothers (p ≥ 0.16). All four
polymorphisms remained significant pre-
dictors of PON1 activity in Caribbean-
Hispanic mothers (p ≤ 0.05).
For neonates, the geometric mean
PON1 activity was dependent on race/
ethnicity: 44.4 (referent), 33.3 (p < 0.002),
and 25.4 (p < 0.0001) U/mL for African
Americans, Caribbean Hispanics, and
Caucasians, respectively. Effects of neonate
genotypes and race/ethnicity on neonate
PON1 activity are summarized in Table 3.
Similar to the mothers, the three promoter
polymorphisms as well as L55M (but
not Q192R) were significantly associated
with PON1 activity (p < 0.0001). Unlike
the mothers, these associations were
Toxicogenomics | Genotype–phenotype analysis of PON1
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Table 1. Allele frequencies of PON genotypes.
Gene, Mother Neonate
position Caucasian African American Hispanic Caucasian African American Hispanic
and allele (n = 82) (n = 117) (n = 203) (n = 56) (n = 66) (n = 107)
PON1
–909
G 0.38 0.84 0.61 0.42 0.88 0.65
C 0.62 0.16 0.39 0.58 0.12 0.35
–162
A 0.20 0.42 0.26 0.18 0.42 0.25
G 0.80 0.58 0.74 0.82 0.58 0.75
–108
C 0.38 0.85 0.65 0.44 0.89 0.67
T 0.62 0.15 0.35 0.56 0.11 0.33
55
L 0.54 0.79 0.71 0.58 0.81 0.78
M 0.46 0.21 0.29 0.42 0.19 0.22
192
Q 0.73 0.37 0.54 0.76 0.30 0.50
R 0.27 0.63 0.46 0.24 0.70 0.50
PON2
311
S 0.80 0.79 0.77 0.75 0.73 0.77
C 0.20 0.21 0.23 0.25 0.27 0.23
Table 2. Maternal PON1 polymorphism frequencies, enzyme activities, and p-values for trend.
Caucasian (n = 78)  African American (n = 112)  Hispanic (n = 200)  Combined (n = 390)
Mean PON1  Mean PON1  Mean PON1  Mean PON1 
Position and  enzyme activity p-Value enzyme activity p-Value enzyme activity p-Value enzyme activity p-Value
genotype %  (n) (SD) (trend)a % (n) (SD) (trend)a % (n) (SD) (trend)a % (n) (SE)b (trend)a
–909
GG  15 (12) 160.5 (16.3) 72 (80) 129.0 (28.5) 38 (76) 148.4 (34.6) 43 (168) 143.7 (2.7)
CG  45 (35) 135.0 (33.2) p = 0.0009 24 (27) 123.0 (29.0) p = 0.28 47 (93) 134.1 (32.6) p < 0.0001 40 (155) 130.6 (2.7) p < 0.0001
CC  40 (31) 122.5 (29.1) 4 (4) 120.8 (40.9) 16 (31) 109.7 (33.8) 17 (66) 111.4 (4.1)
–162
AA 8 (6) 159.5 (17.2) 21 (23) 128.5 (31.4) 7 (13) 146.6 (42.6) 10 (42) 140.7 (5.2)
AG 24 (19) 139.5 (26.6) p = 0.02 43 (48) 130.1 (27.2) p = 0.35 39 (78) 139.9 (33.1) p = 0.05 37 (145) 136.4 (2.9) p = 0.02
GG 68 (53) 129.0 (33.5) 36 (40) 122.5 (29.8) 55 (109) 131.4 (36.6) 52 (202) 127.5 (2.4)
–108
CC 14 (11) 161.6 (16.6) 72 (81) 129.1 (28.3) 44 (88) 150.9 (34.6) 46 (180) 145.9 (2.6)
CT 46 (36) 134.0 (27.8) p = 0.001 25 (28) 122.4 (28.8) p = 0.16 42 (84) 129.9 (28.7) p < 0.0001 38 (148) 127.9 (2.7) p < 0.0001
TT 40 (31) 124.0 (35.1) 3 (3) 113.9 (46.9) 14 (28) 105.7 (35.8) 16 (62) 109.3 (4.1)
55
LL 33 (26) 139.8 (28.6) 58 (65) 134.0 (27.5) 51 (101) 149.3 (31.7) 49 (192) 143.5 (2.4)
LM 42 (33) 133.3 (45.5) p = 0.14 39 (44) 118.8 (27.7) p = 0.001 43 (85) 123.9 (35.2) p < 0.0001 42 (162) 124.2 (2.6) p = <0.0001
MM 24 (19) 126.9 (34.3) 3 (3) 96.5 (32.3) 7 (14) 110.1 (29.8) 9 (36) 114.6 (5.4)
192
QQ 55 (43) 138.1 (33.4) 14 (16) 116.8 (32.5) 29 (57) 134.1 (42.1) 30 (116) 131.7 (3.2)
QR 35 (27) 130.6 (31.0) p = 0.22 44 (49) 133.2 (31.2) p = 0.67 51 (101) 137.0 (33.9) p = 0.55 45 (177) 134.2 (2.7) p = 0.74
RR 10 (8) 122.7 (24.7) 42 (47) 124.1 (23.7) 21 (42) 134.8 (31.7) 25 (97) 129.4 (3.6)
ap-Value for trend on log-transformed values. bLeast-squares means adjusted for mother’s race/ethnicity.apparent in all three race/ethnicity groups
(p = 0.02).
Figure 1 compares the genetic
inﬂuences of the three promoter and L55M
polymorphisms on PON1 activity in
mothers and their neonates (all race/ethnic-
ities combined). There was a striking dif-
ference in the PON1 activities, with the
neonates having a geometric mean 4.1-fold
lower. In addition, the genetic inﬂuence in
neonates appears to be stronger, with no
polymorphisms affecting maternal PON1
activity by more than 35% but with both
–108 (and –909) and L55M polymor-
phisms affecting PON1 activity by more
than 2-fold in neonates.
PON Linkage Disequilibrium:
Important Alleles Affecting
PON1 Activity
Pairwise LD calculations for the five
polymorphisms and three race/ethnicities,
reported as D´ and chi-square with associ-
ated p-values, are presented in Table 4. In
all three race/ethnicities, the promoter poly-
morphisms are in nearly complete LD with
one another (D´ ≥ 0.9, p < 0.0001). The
promoter polymorphisms are also in signiﬁ-
cant LD with L55M, but more so for
Caucasians than for African Americans.
L55M and Q192R are in LD in Caucasians
but not in African Americans. On the other
hand, the promoter polymorphisms
–108C→T and –909G→C are in signifi-
cant LD with Q192R in African-Americans
but not in Caucasians. Interestingly, strong
LD is observed between PON2 C311S and
the PON1 promoter polymorphisms in all
race/ethnicities, with the strongest linkage
in Caucasians. In all of these cases, values
for Caribbean Hispanics fall between those
for Caucasians and African Americans.
Analysis of conditional variance
(adjusted for the other polymorphisms
based on Brophy et al. 2001b) showed that
maternal –108C→T and L55M polymor-
phisms contributed 12 and 4%, 1 and 9%,
and 17 and 12% of the total variance,
respectively, for Caucasians, African
Americans, and Caribbean Hispanics. A
similar analysis of conditional variance for
neonates showed that the –108C→T
and L55M polymorphisms contributed
53 and 44%, 8 and 3%, and 19 and 10%
of the total variance, respectively, for
Caucasians, African Americans, and
Caribbean Hispanics.
Table 5 shows the maternal PON1
activities for the nine possible –108C→T
and L55M genotypes. Using –108CC,
55LL as referent, all three L55M geno-
types of –108TT were significantly differ-
ent, with decreasing PON1 activity trend
from 55LL (126.6 U/mL) to 55LM
(116.1 U/mL) to 55MM (105.1 U/mL).
With the same referent, only the –108TT
genotype of 55MM was significantly dif-
ferent, although the sample sizes were low
(7 and 9) for the other –108 genotypes.
Discussion
PON1 Allele Frequencies
In this study we have investigated the effect
of genotype, as reﬂected by all of these ﬁve
common PON1 polymorphisms, on phe-
notype, as reﬂected by PON1 activity. The
subjects were pregnant women and their
neonates at risk of prenatal exposure to
chlorpyrifos in the home. The subjects
included Caucasians, African Americans,
and Caribbean Hispanics. The observed
frequencies (Table 1) for the 192R allele
among Caucasians and African Americans
were consistent with previous studies [e.g.,
0.28 for Caucasians compared with
0.27–0.31 in several previous studies
(Davies et al. 1996; Leviev and James
2000; Brophy et al. 2001b)]. The allele fre-
quencies for all five PON1 SNPs and for
PON2 S311C among Caribbean Hispanics
in New York City fell between the values
for Caucasians and African Americans,
with allele frequencies consistent with simi-
lar Caucasian and African-American
derivation. This study was the first to
include all of these polymorphisms and
these race/ethnicities in a study of PON1
activity in mothers and their neonates.
PON1 Genotypes and PON1 
Activity: Increased Genotypic
Inﬂuence in Neonates
It has been known for many years that
neonates have much lower PON1 activities
than adults (Mueller et al. 1983). We have
confirmed this observation for each of the
race/ethnicities (Tables 2 and 3, Figure 1).
Specifically, the mean PON1 activity in
maternal blood was 4.6, 3.6, and 2.6 times
greater than the mean PON1 activity in
cord blood for Caucasians, Caribbean
Hispanics, and African Americans,
respectively. Again, the data for Caribbean
Hispanics fall between Caucasians and
African Americans. For all groups, however,
the results suggest a potentially greater
Toxicogenomics | Chen et al.
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Table 3. Neonate PON1 polymorphism frequencies, enzyme activities, and p-values for trend.
Caucasian (n = 47)  African American (n = 51)  Hispanic (n = 91)  Combined (n = 189)
Mean PON1  Mean PON1  Mean PON1  Mean PON1 
Position and  enzyme activity p-Value enzyme activity p-Value enzyme activity p-Value enzyme activity p-Value
genotype %  (n) (SD) (trend)a % (n) (SD) (trend)a % (n) (SD) (trend)a % (n) (SE)b (trend)a
–909
GG  15 (7) 41.8 (12.4) 75 (38) 52.4 (23.9) 40 (36) 42.8 (14.9) 43 (81) 47.1 (2.2)
CG  53 (25) 32.2 (18.2) p < 0.0001 25 (13) 36.4 (12.8) p = 0.005 51 (46) 37.6 (23.9) p = 0.006 44 (84) 35.8 (2.1) p < 0.0001
CC  32 (15) 18.5 (7.7) — — 10 (9) 37.6 (23.9) 13 (24) 35.8 (2.1)
–162
AA 2 (1) 63.1 18 (9) 51.8 7 (7) 45.7 8 (17) 49.7
AG 32 (15) 38.5 (20.5) p = 0.0004 48 (24) 53.2 (29.3) p = 0.08 41 (37) 41.3 (15.9) p = 0.02 40 (76) 44.3 (2.3) p < 0.0001
GG 66 (31) 23.7 (10.7) 34 (17) 40.2 (11.4) 52 (47) 34.9 (24.1) 50 (95) 32.3 (2.1)
–108
CC 17 (8) 50.5 (23.1) 76 (39) 51.8 (23.8) 48 (43) 46.3 (23.5) 48 (90) 49.0 (2.0)
CT 51 (24) 28.8 (11.0) p < 0.0001 24 (12)  36.8 (13.3) p = 0.01 41 (37) 33.2 (13.9) p = 0.0004 39 (73) 32.4 (2.2) p < 0.0001
TT 32 (15) 18.5 (7.7) — — 11 (10) 37.6 (23.9) 13 (25) 35.8 (2.1)
55
LL 32 (15) 41.0 (21.1) 71 (36) 52.0 (22.5) 60 (55) 42.8 (21.9) 56 (106) 45.6 (1.9)
LM 51 (24) 27.5 (9.1) p < 0.0001 25 (13) 40.7 (21.7) p = 0.004 35 (32) 33.0 (15.3) p = 0.0007 36 (69) 32.6 (2.4) p < 0.0001
MM 17 (8) 12.5 (5.6) 4 (2) 29.6 (15.3) 4 (4) 19.0 (19.4) 7 (14) 17.2 (5.3)
192
QQ 64 (30) 28.4 (14.9) 8 (4) 47.5 (29.8) 25 (23) 40.3 (20.5) 30 (57) 39.2 (2.9)
QR 30 (14) 30.9 (21.7) p = 0.50 43 (22) 48.5 (27.6) p = 0.59 53 (48) 39.1 (22.5) p = 0.33 44 (84) 39.4 (2.3) p = 0.08
RR 6 (3) 30.0 (8.2) 49 (25) 48.2 (17.0) 22 (20) 34.1 (14.9) 25 (48) 36.6 (3.1)
ap-Value for trend on log-transformed values. bLeast-squares means adjusted for neonate’s race/ethnicity.degree of susceptibility of a fetus or newborn
to the toxic effects of organophosphates.
Effects of functional polymorphisms in
the coding region of a gene (e.g., L55M
and Q192R) normally remain constant
throughout the life of an individual.
Polymorphisms in the promoter region of a
gene (e.g., –909, –168, –108) can affect
the level of transcription. We hypothesized
that transcription factor interactions with
the promoter may vary throughout life.
PON1 activity differed among genotypes
for promoter polymorphisms, as exempli-
fied by –108C→T, and the functional
polymorphism L55M. A significant effect
of Q192R on PON1 activity was found in
one large recent study (Brophy et al.
2001b). Our results for all race/ethnicities
individually as well as combined agree with
a second recent study showing no signifi-
cant effect (Leviev and James 2000), but
this lack of effect may be due to smaller
sample size. In our combined maternal
population, the –108CC and –108TT
homozygotes as well as the 55LL and
55MM homozygotes had approximately
15% greater and lesser activities than the
corresponding heterozygotes, respectively.
The effect of the promoter polymorphisms
in African-American mothers did not reach
the level of significance, probably because
of sample size considering the lower minor
allele frequency. Another study found 20
and 12% for the –108 and L55M poly-
morphisms, respectively (Leviev and James
2000), and a third study found about 27
and 20%, respectively (Brophy et al.
2001b). All of these results are similar and
are strikingly different from our results
with cord blood.
In particular, in our combined neonate
population, the –108CC and –108TT
homozygotes as well as the 55LL and
55MM homozygotes had approximately 51
and 40% greater and 28 and 47% lesser
activities than the corresponding heterozy-
gotes, respectively. Thus, not only is the
average potential risk to a fetus or newborn
from organophosphate exposure greater
than in the adult, the range of protection
afforded by PON1 is more dependent on
genotype than in the adult, with the
–108TT and the 55MM homozygotes hav-
ing PON1 activities 5.8- and 7.8-fold lower
than the average adult, respectively.
PON Linkage Disequilibrium:
Important Alleles Affecting PON1
Activity
As previously observed (Leviev and James
2000; Brophy et al. 2001b), the promoter
polymorphisms were in significant LD
(Table 4). Examination of maternal
PON1 activity and genotypes confirmed
that nearly all of the contribution of these
polymorphisms to PON1 activity could
be determined by analyzing the –108
polymorphism.
The LD extends to L55M and
–108C→T, but is less than among the pro-
moter polymorphisms, with D´ varying
from 0.42 to 0.51 depending on race/
ethnicity. After correction for LD, Leviev
and James (2000) and Brophy et al.
(2001b) found that the –108CT polymor-
phism accounted for 24.7 and 22.8%,
respectively, of the variance in PON1 for
Caucasians. They also found that L55M
accounted for 4.4–4.6 or 4.1% of the
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Figure 1. PON1 activity by genotype, all race/ethnicities combined for mothers and neonates. Normal refers to
the allele with the highest PON1 activity. Genotypes: (A) –909G→C; (B) –162A→G; (C) –108C→T; (D) L55M. (A, C,
D) Maternal and neonate p-value for trend < 0.0001. (B) Maternal p-value for trend = 0.02; neonate p-value for
trend < 0.0001. 
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Table 4. Tests of LD between maternal PON polymorphisms: D’, chi-square, and associated p-values.
Position: PON1 –909 –162 55 192 PON2 –311
D’ Chi-square (p) D’ Chi-square (p) D’ Chi-square (p) D’ Chi-square (p) D’ Chi-square (p)
Caucasian
–108 0.92 119.38 (p < 0.0001) –1.00 51.44 (p < 0.0001) 0.50 12.71 (p < 0.001) 0.16 0.40 (p = NS) –0.82 32.08 (p < 0.0001)
–909 –1.00 52.83 (p < 0.0001) 0.60 18.82 (p < 0.0001) 0.02 0.01 (p = NS) –0.88 38.89 (p < 0.0001)
–162 –1.00 30.99 (p < 0.0001) –0.77 5.88 (p < 0.02) 0.37 14.04 (p < 0.001)
55 –0.93 33.85 (p < 0.0001) –0.43 4.30 (p < 0.05)
192 –0.02 0.00 (p = NS)
African American
–108 0.97 126.06 (p < 0.0001) –0.90 20.73 (p < 0.0001) 0.42 11.45 (p < 0.001) –0.43 7.49 (p < 0.01) –1.00 7.05 (p < 0.01)
–909 –1.00 28.23 (p < 0.0001) 0.35 8.41 (p < 0.01) –0.34 4.99 (p < 0.05) –0.99 7.81 (p < 0.01)
–162 –0.44 4.71 (p < 0.05) –0.11 1.06 (p = NS) 0.10 0.36 (p = NS)
55 –0.18 1.72 (p = NS) 0.03 0.14 (p = NS)
192 –0.25 3.23 (p = NS)
Hispanic
–108 0.90 213.47 (p < 0.0001) –1.00 61.33 (p < 0.0001) 0.51 38.22 (p < 0.0001) –0.29 8.76 (p < 0.01) –0.87 25.38 (p < 0.0001)
–909 –1.00 73.61 (p < 0.0001) 0.47 24.77 (p < 0.0001) –0.22 5.02 (p < 0.05) –0.95 42.09 (p < 0.0001)
–162 –0.72 15.24 (p < 0.0001) –0.15 1.23 (p = NS) 0.36 20.21 (p < 0.0001)
55 –0.50 18.72 (p < 0.0001) –0.25 1.21 (p = NS)
192 –0.04 0.07 (p = NS)
NS, not signiﬁcant.variance, respectively. Our data for
Caucasian mothers were qualitatively con-
sistent, with conditional variances attribut-
able to –108C→T being greater than that
attributable to L55M, at 12 and 4%,
respectively, after adjustment for the other
polymorphisms. In Table 5, PON1 activity
for all three L55M genotypes combined
with –108TT were significantly different
from the referent (55LL, –108CC, p <
0.02) and decreased from 126.6 (55LL) to
116.1 (55ML) to 105.1 (55MM) U/mL.
Although the number of neonates was
smaller than the number of mothers, the
conditional variance attributable to genes
was greater, and both polymorphisms again
contributed significantly. Taken together,
these data suggest that analysis of both
–108C→T and L55M PON1 genotypes is
required to infer phenotype from genotype.
LD for Q192R depended strongly on
race/ethnicity, with D´ to –108C→T being
–0.93 (p < 0.0001) in Caucasians and
–0.18 (not significant) in African
Americans. The reverse was seen for
L55M and Q192R, with D´ being –0.43
(p < 0.01) in African Americans and 0.16
(not signiﬁcant) in Caucasians. As expected,
D´ values for Caribbean Hispanics fell
between those for Caucasians and African
Americans. Although Q192R had no signif-
icant effect on PON1 activity as measured
using phenyl acetate as the substrate, this
polymorphism affects substrate specificity
and thus affects the enzymatic activity with
other substrates, such as chlorpyrifos oxon,
both in vitro and in vivo (Furlong et al.
2000). Therefore, for other substrates,
Q192R genotype must also be determined
to infer phenotype from genotype, and the
race/ethnicity dependence of LD must be
taken into account.
Linkage disequilibrium depends on
local recombination rate (Taillon-Miller
et al. 2000), population structure, and the
number of generations since the mutation
(polymorphism) arose (Slatkin 1999).
There has been a significant debate over
the size of the DNA blocks exhibiting LD
(Reich et al. 2001; Dunning et al. 2000;
Abecasis et al. 2001). In this study we also
looked at LD between the PON1 polymor-
phisms and PON2 C311S located 97.2 kb
away from Q192R and more distant from
the other PON1 polymorphisms. PON2
C311S exhibits significant LD only in
Caucasians for PON1 L55M (D´ = –0.43,
p < 0.05) and no linkage for PON1
Q192R. However, PON2 C311S was
highly linked to PON1 –108C→T in all
three race/ethnicities. It is of interest to
note that both PON1 (Imai et al. 2000)
and PON2 (Sanghera et al. 1998) poly-
morphisms have been linked to cardio-
vascular disease, although a mechanism for
PON2 action has not been demonstrated
(Mackness et al. 1999). The LD demon-
strated in this work may facilitate similar
epidemiologic analyses.
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